On the morning of April 18, the signing ceremony of Second-stage Sino-U.S. Strategic Cooperation in Antibody and Cellular Immunotherapy Engineering Research in the Letter of Intent for Second-stage Strategic Cooperation in Scientific and Clinical Research was launched between the First Affiliated Hospital of Xi’an Jiaotong University and Eureka Therapeutics Inc. in the U.S.

Professor Chen Teng, Assistant to President of Xi 'an Jiaotong University, Secretary of Party Working Committee and Deputy Director of Health Science Center of Xi 'an Jiaotong University, Professor Shi Bingyin, President of our hospital, Professor Yuan Zuyi, Vice President of our hospital, Chief Physician Liu Huasheng, Academic Assistant to Director of Department of Hematology, experts from other clinical departments and the leaders of Department of Science and Technology, Clinical Pharmacology Institution, Clinical Research Center, Operation Department and President Office attended the signing ceremony. President Shi Bingyin delivered a welcome speech for visiting our hospital by Dr. Liu Cheng, President and Chief Executive Officer of Eureka Therapeutics Inc.

Eureka Therapeutics Inc. in the U.S. (its wholly-owned subsidiary: Eureka (Beijing) Biotechnology Co., Ltd., Eureka for short) is a biopharmaceutical company in clinical stage, which is dedicated to the research and development of applying immunobiological techniques to treat cancer. In March 2015, bilateral sides signed a strategic cooperation agreement for the first time and officially launched the research work of the "Sino-U.S. Antibody and Cellular Immunotherapy Engineering Research Center". Considering the outstanding achievements in the progress of three international clinical research projects cooperated by the Center, both sides expected to continue the second-stage strategic cooperation in scientific and clinical research in 2019, aiming to establish a world’s first-class platform for scientific and clinical research and clinical translation in immunotherapy. On the basis of smooth operation of GMP laboratory, both sides hoped to establish a novel type of three functional areas: Phase I Clinical Research Ward, GMP New Area for Cellular Immunotherapy and Comprehensive Laboratory and Office Area for Cellular Immunity to conductin vivoandin vitrostudies on the effectiveness and safety, thereby providing the most advanced individualized immunotherapy for patients.